波利特、达克普隆和Nexium对幽门螺杆菌的体外抑菌效果比较

目的：观察、比较质子泵抑制剂(PPI)波利特(雷贝拉唑肠溶衣片)、达克普隆(兰索拉唑胶囊)和Nexium对幽门螺杆菌(Hp)的抑制作用，初步解释近期临床流行病学资料所显示的不同PPI用于Hp根除治疗所表现的明显效果差异现象。方法：使用Hp国际标准株NCTC11637、NCTC11639和国内分离菌株CAPMN62，应用平板掺入法测定三种PPI对Hp的体外抑菌作用。结果：波利特在体外对Hp具有明显的抑制作用(MIC99为2．25mg／L)，其次为达克普隆(MIC99为42.5mg／L)，而Nexium抑菌作用不明显(MIC99为360mg／L)。结论：不同PPI对Hp的直接抑菌作用存在明显差异，其作用除本身化学结构的差异因素外，制剂中的其他复合成分的影响也不容忽视；亟待对体外抑菌效果与用于Hp感染治疗效果的相关性进行分析，以便更好地指导临床用药和相关幽门螺杆菌病的防治。

In-vitro activity of rabeprazole lansoprazole and esomeprazole against Helicobacter pylori

Objective To investigate the antimicrobial activity of Pariet, Tekpron, Nexium, respectively, against Helicobacter pylori (H.pylori ) in vitro. Methods Antimicrobial effects of these medicines were evaluated through detertion of MICs for 3 H.pylori strains isolated from different countries. Results The MIC 99 contents were 2.25 mg/L, 42.5 mg/L and 360 mg/L, respectively, for the three medicines. The strains under testing exhibited the same susceptibility to each medicine. Nexium did not inhibit the bacteria under the concentration of 3.6-36 mg/L with more and bigger H.pylori colonies seen when compared with controls. Conclusions The growth inhibitory activity appeared to be different among the three PPI medicines under investigation, with Rabeprazole the most potential agent of the three. Data suggested that the action of growth inhibition in vitro was resting on the characteristic of the given PPI as well as the supplements of the medicine.